Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRL 
Charles River Laboratories (CRL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CRL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $177.73
1 Year Target Price $177.73
| 4 | Strong Buy |
| 0 | Buy |
| 14 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.47% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.49B USD | Price to earnings Ratio - | 1Y Target Price 177.73 |
Price to earnings Ratio - | 1Y Target Price 177.73 | ||
Volume (30-day avg) 19 | Beta 1.47 | 52 Weeks Range 91.86 - 230.02 | Updated Date 09/17/2025 |
52 Weeks Range 91.86 - 230.02 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.66% | Operating Margin (TTM) 16.67% |
Management Effectiveness
Return on Assets (TTM) 4.31% | Return on Equity (TTM) -1.81% |
Valuation
Trailing PE - | Forward PE 14.79 | Enterprise Value 10064083384 | Price to Sales(TTM) 1.86 |
Enterprise Value 10064083384 | Price to Sales(TTM) 1.86 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 19.05 | Shares Outstanding 49214200 | Shares Floating 48623116 |
Shares Outstanding 49214200 | Shares Floating 48623116 | ||
Percent Insiders 1 | Percent Institutions 105.66 |
Upturn AI SWOT
Charles River Laboratories
Company Overview
History and Background
Charles River Laboratories was founded in 1947 by Henry Foster as Charles River Breeding Laboratories to provide research animals. Over time, it expanded its services through acquisitions and internal growth, evolving into a leading provider of research models, preclinical and clinical laboratory services.
Core Business Areas
- Research Models and Services (RMS): Provides research models, related services, and genetic testing. This segment focuses on breeding and genetically characterizing laboratory animals used in research.
- Discovery and Safety Assessment (DSA): Offers preclinical research services, including drug discovery, safety assessment, and pharmacology studies to help clients identify and develop new therapies. This segment includes early-stage drug development.
- Manufacturing Solutions: Provides products and services to support the manufacturing of biopharmaceuticals. This segment includes biologics testing, cell therapy manufacturing, and microbial solutions.
Leadership and Structure
James C. Foster is the Chairman, President, and Chief Executive Officer. The company operates with a structured management team overseeing each business segment and functional area.
Top Products and Market Share
Key Offerings
- Research Models: Provides genetically defined laboratory animals, primarily rodents, for use in preclinical research. Charles River is the leading supplier of laboratory animals globally, estimated at over 30% market share. Competitors include Envigo (acquired by Inotiv), Taconic Biosciences, and Janvier Labs.
- Safety Assessment Services: Offers preclinical safety testing services to assess the safety and efficacy of drug candidates. This market is highly competitive, with players like WuXi AppTec, Labcorp (Covance), and Eurofins Scientific. Charles River has a significant market share, estimated between 10-15%.
- Biologics Testing Solutions: This involves testing services to ensure the safety and quality of biologics during manufacturing. The biologics testing market is growing rapidly, with competitors like SGS, Eurofins, and Nelson Labs. Charles River's market share is estimated at 5-10%.
Market Dynamics
Industry Overview
The preclinical research and drug development services industry is characterized by technological advancements, increasing regulatory requirements, and growing demand for new therapies. Outsourcing of research activities is a key trend.
Positioning
Charles River is a global leader in preclinical and clinical laboratory services, with a diversified portfolio and a strong reputation for quality and scientific expertise. It benefits from long-term relationships with pharmaceutical and biotechnology companies.
Total Addressable Market (TAM)
The global preclinical CRO market is estimated to be worth over $80 billion. Charles River Laboratories is well-positioned to capture a significant portion of this market through its diverse service offerings and global presence.
Upturn SWOT Analysis
Strengths
- Global Leader in Research Models
- Diversified Service Portfolio
- Strong Reputation for Quality
- Long-Term Client Relationships
- Experienced Management Team
Weaknesses
- High Dependence on Pharmaceutical Industry
- Exposure to Regulatory Changes
- Competition in Safety Assessment Services
- Integration Risks from Acquisitions
- Sensitivity to Economic Downturns
Opportunities
- Growth in Biopharmaceutical Development
- Expansion in Cell and Gene Therapy
- Increasing Outsourcing of Research Activities
- Geographic Expansion in Emerging Markets
- Development of Innovative Technologies
Threats
- Economic Slowdowns
- Pricing Pressure from Competitors
- Changes in Regulatory Requirements
- Animal Rights Activism
- Scientific Advancements Rendering Existing Models Obsolete
Competitors and Market Share
Key Competitors
- LH
- WRBY
- CDXS
Competitive Landscape
Charles River benefits from its scale and diversified service offerings, but faces strong competition from specialized CROs and larger, diversified healthcare companies.
Major Acquisitions
Cognex Biosciences
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Expand capabilities in cell and gene therapy, supporting manufacturing solutions.
VETSCAN IMAGYST
- Year: 2023
- Acquisition Price (USD millions): 380
- Strategic Rationale: Expands capabilities in digital pathology.
Growth Trajectory and Initiatives
Historical Growth: Charles River has historically grown through organic expansion and strategic acquisitions, particularly in the DSA and Manufacturing Solutions segments.
Future Projections: Analysts predict continued growth driven by increasing demand for preclinical research services, biopharmaceutical development, and cell and gene therapy manufacturing.
Recent Initiatives: Recent initiatives include acquisitions to expand service offerings, investments in new technologies, and expansion into new geographies.
Summary
Charles River Laboratories is a leading provider of preclinical and clinical laboratory services, benefiting from a diversified portfolio and a strong market position. Its growth is driven by the expanding biopharmaceutical industry and increasing outsourcing trends. While facing competition and economic uncertainties, Charles River is well-positioned for long-term growth through strategic acquisitions and investments in innovative technologies. Animal rights issues and changing regulations are key risk factors. They should focus on growth and innovation, especially in the cell and gene therapy space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions are time sensitive and change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Charles River Laboratories
Exchange NYSE | Headquaters Wilmington, MA, United States | ||
IPO Launch date 2000-06-23 | Chairman, President & CEO Mr. James C. Foster J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18700 | Website https://www.criver.com |
Full time employees 18700 | Website https://www.criver.com | ||
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.